{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:13:59Z","timestamp":1775891639643,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21372050"],"award-info":[{"award-number":["21372050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22077018"],"award-info":[{"award-number":["22077018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004179","name":"Ningxia Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004179","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejmech.2022.114512","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:39:17Z","timestamp":1654303157000},"page":"114512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Expansion of the S\u2013CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase"],"prefix":"10.1016","volume":"238","author":[{"given":"Xu","family":"Ling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Qing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik De","family":"Clercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen-Er","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114512_bib1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114512_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2022.114512_bib3","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.2174\/092986711795843209","article-title":"Recent Advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"18","author":"Yu","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib4","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development: current innovations and future trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2336","article-title":"HIV drug development: the next 25 years","volume":"6","author":"Flexner","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114512_bib6","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1021\/acs.jmedchem.1c01758","article-title":"Contemporary medicinal chemistry strategies for the discovery and development of novel HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2022.114512_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.coph.2020.10.005","article-title":"Design strategies for long-acting anti-HIV pharmaceuticals","volume":"54","author":"Sang","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114512_bib9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cclet.2019.11.020","article-title":"Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors","volume":"31","author":"Han","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114512_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0223-5234(92)90009-P","article-title":"Synthesis, antimicrobial and antiviral activities of isotrimethoprim and some related derivatives","volume":"27","author":"Botta","year":"1992","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib11","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1016\/j.bmc.2011.05.024","article-title":"Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"19","author":"Zhang","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cmdc.201000555","article-title":"Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonylmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs","volume":"6","author":"Yu","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114512_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.apsb.2019.08.009","article-title":"Synthesis and biological evaluation of a series of 2-(((5-akly\/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114512_bib14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/acs.jmedchem.8b01238","article-title":"Effect of \u03b1-methoxy substitution on the anti-HIV activity of dihydropyrimidin-4(3H)-ones","volume":"62","author":"Nawrozkij","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib15","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1021\/jm00017a010","article-title":"Preparation and anti-HIV-1 activity of thio analogues of dichydroalkoxybenzyloxopyrimidines","volume":"38","author":"Mai","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib16","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.bmcl.2004.04.008","article-title":"5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series","volume":"14","author":"He","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114512_bib17","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1016\/j.bmc.2008.01.039","article-title":"Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"16","author":"Wang","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bioorg.2004.05.007","article-title":"Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones","volume":"32","author":"He","year":"2004","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib19","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1016\/j.bmc.2013.08.040","article-title":"Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies","volume":"21","author":"Wu","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib20","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1021\/jm061167r","article-title":"Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or \u03b1-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"50","author":"Ji","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1039\/c3md00247k","article-title":"Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase","volume":"5","author":"Wu","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2022.114512_bib22","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ejmech.2008.06.028","article-title":"Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"44","author":"Wang","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ardp.200400961","article-title":"Non-nucleoside HIV reverse transcriptase inhibitors, Part 6[1]: synthesis and anti-HIV activity of novel 2-[(arylcarbonylmethyl)thio]-6-arylthio DABO analogues","volume":"338","author":"Sun","year":"2005","journal-title":"Arch. Pharmazie"},{"key":"10.1016\/j.ejmech.2022.114512_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/cbdv.200890008","article-title":"Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10","volume":"5","author":"Wang","year":"2008","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2022.114512_bib25","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1021\/acs.jmedchem.1c01676","article-title":"Discovery of novel pyridine-dimethyl-phenyl-DAPY hybrids by molecular fusing of methyl-pyrimidine-DAPYs and difluoro-pyridinyl-DAPYs: improving the druggability toward high inhibitory activity, solubility, safety, and PK","volume":"65","author":"Ding","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib26","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1021\/acs.jmedchem.1c00708","article-title":"Improving druggability of novel diarylpyrimidine NNRTIs by a fragment-based replacement strategy: from biphenyl-DAPYs to heteroaromatic-biphenyl-DAPYs","volume":"64","author":"Ding","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib27","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1021\/acs.jmedchem.1c00128","article-title":"Hydrophobic pocket occupation design of difluoro-biphenyl-diarylpyrimidines as non-nucleoside HIV-1 reverse transcriptase inhibitors: from N-alkylation to methyl hopping on the pyrimidine ring","volume":"64","author":"Ding","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/med.21760","article-title":"Druggability modification strategies of the diarylpyrimidine-type non-nucleoside reverse transcriptase inhibitors","volume":"41","author":"Ding","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2022.114512_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.coph.2020.09.017","article-title":"Recent discoveries in HIV-1 reverse transcriptase inhibitors","volume":"54","author":"Gu","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114512_bib30","doi-asserted-by":"crossref","first-page":"11430","DOI":"10.1021\/acs.jmedchem.9b01446","article-title":"Ligand-based design of nondimethylphenyl-diarylpyrimidines with improved metabolic stability, safety, and oral pharmacokinetic profiles","volume":"62","author":"Sang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/acsmedchemlett.6b00025","article-title":"Design and synthesis of 2-alkylpyrimidine-4,6-diol and 6-alkylpyridine-2,4-diol as potent GPR84 agonists","volume":"7","author":"Liu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114512_bib32","doi-asserted-by":"crossref","first-page":"7888","DOI":"10.1021\/acs.jmedchem.5b00983","article-title":"Discovery and optimization of a series of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors through fragment screening, structure-based design, and parallel synthesis","volume":"58","author":"Shipe","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib33","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1021\/acs.jmedchem.5b01979","article-title":"Development and in vitro evaluation of a microbicide gel formulation for a novel non-nucleoside reverse transcriptase inhibitor belonging to the N-dihydroalkyloxybenzyloxopyrimidines (N-DABOs) family","volume":"59","author":"Tintori","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib34","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ejmech.2018.07.035","article-title":"6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H","volume":"156","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib35","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1021\/jm00378a016","article-title":"Novel pyrimidine and 1,3,5-triazine hypolipemic agents","volume":"27","author":"D'Atri","year":"1984","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib36","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1021\/acsinfecdis.7b00275","article-title":"2-Mercapto-Quinazolinones as inhibitors of type II NADH dehydrogenase and mycobacterium tuberculosis: structure\u2013activity relationships, mechanism of action and absorption, distribution, metabolism, and excretion characterization","volume":"4","author":"Murugesan","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114512_bib37","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1021\/acs.jmedchem.5b00140","article-title":"Studies on the ATP binding site of fyn kinase for the identification of new inhibitors and their evaluation as potential agents against tauopathies and tumors","volume":"58","author":"Tintori","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib38","doi-asserted-by":"crossref","first-page":"8336","DOI":"10.1021\/jo201501f","article-title":"Synthesis of bridgehead-substituted azabicyclo[2.2.1]heptane and -[3.3.1]nonane derivatives for the elaboration of \u03b17 nicotinic ligands","volume":"76","author":"Slowinski","year":"2011","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib39","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1021\/acs.orglett.7b01504","article-title":"Total syntheses of festuclavine, Pyroclavine, Costaclavine, epi-Costaclavine, Pibocin A, 9-Deacetoxyfumigaclavine C, Fumigaclavine G, and Dihydrosetoclavine","volume":"19","author":"Liu","year":"2017","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2022.114512_bib40","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1039\/C7OB02828H","article-title":"Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored \u201chydrophobic channel\u201d","volume":"16","author":"Zhou","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113868","article-title":"Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel","volume":"226","author":"Jin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib42","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1021\/jm010853h","article-title":"Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]- 3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase","volume":"44","author":"Mai","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib43","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/jm0309856","volume":"47","author":"Ragno","year":"2004","journal-title":"J. Med. Chem."},{"issue":"Suppl 2","key":"10.1016\/j.ejmech.2022.114512_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0213-005X(09)73216-1","article-title":"[Etravirine drug interactions]","volume":"27","author":"P\u00e9rez","year":"2009","journal-title":"Enferm. Infecc. Microbiol. Cl\u00edn."},{"key":"10.1016\/j.ejmech.2022.114512_bib45","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1021\/acs.jmedchem.0c00117","article-title":"Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties","volume":"63","author":"Kang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib46","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/dmd.31.8.1005","article-title":"In vitro drug interacitons of cytochrome p450: an evaluation of fluorogenic to conventional substrates","volume":"31","author":"Cohen","year":"2003","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.ejmech.2022.114512_bib47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.apsb.2019.09.007","article-title":"Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"10","author":"Jin","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114512_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: Useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114512_bib49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21445","article-title":"Development of safe drugs: the hERG Challenge","volume":"38","author":"Kalyaanamoorthy","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2022.114512_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1359-6446(04)03278-7","article-title":"Predictive in silico modeling for hERG channel blockers","volume":"10","author":"Aronov","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114512_bib51","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/13543776.2017.1303046","article-title":"Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1","volume":"27","author":"Kang","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2022.114512_bib52","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nprot.2007.517","article-title":"Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later","volume":"3","author":"Pannecouque","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2022.114512_bib53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0166-0934(88)90134-6","article-title":"Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds","volume":"20","author":"Pauwels","year":"1988","journal-title":"J. Virol Methods"},{"key":"10.1016\/j.ejmech.2022.114512_bib54","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1006\/viro.1993.1027","article-title":"HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase","volume":"192","author":"Balzarini","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2022.114512_bib55","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1128\/jvi.67.9.5353-5359.1993","article-title":"Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy","volume":"67","author":"Balzarini","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2022.114512_bib56","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1073\/pnas.90.15.6952","volume":"90","author":"Balzarini","year":"1993","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2022.114512_bib57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/mol.61.2.400","article-title":"Chimeric human immunodeficiency virus Type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance\/rensitivity to non-nucleoside reverse transcriptase inhibitors","volume":"61","author":"Auwerx","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114512_bib58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/abio.1997.2177","article-title":"Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation","volume":"249","author":"Singer","year":"1997","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2022.114512_bib59","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1021\/acschemneuro.8b00605","article-title":"Neuroprotective effect of swertiamain on cerebral ischemia\/reperfusion injury by inducing the Nrf2 protective pathway","volume":"10","author":"Wang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114512_bib60","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1021\/jm4017174","article-title":"Rapid identification of Keap1\u2013Nrf2 small-molecule inhibitors through structure-based virtual screening and hit-based substructure search","volume":"57","author":"Zhuang","year":"2014","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T14:14:14Z","timestamp":1728396854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422004147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":60,"alternative-id":["S0223523422004147"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114512","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expansion of the S\u2013CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114512"}}